ArticleBMC urology2026
Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper tract urothelial carcinoma (UTUC) accounts for approximately 5-10% of urothelial malignancies and is frequently associated with advanced stage and aggressive clinical behavior. In metastatic disease, platinum-based chemotherapy has historically represented standard first-line therapy; however, long-term outcomes remain limited. The combination of enfortumab vedotin and pembrolizumab has recently demonstrated superior survival outcomes compared with platinum-based chemotherapy in advanced urothelial carcinoma. Nevertheless, the depth and durability of response following early discontinuation of antibody-drug conjugate therapy remain incompletely characterized. CASE PRESENTATION: A 38-year-old woman with advanced UTUC developed metastatic progression involving liver, lymph nodes, peritoneum, ovary, and bone following platinum-based chemotherapy and surgery. She received three cycles of enfortumab vedotin plus pembrolizumab. Cross-sectional imaging demonstrated near-complete radiologic response with resolution of hepatic metastases and marked regression of thoracic and abdominal lymphadenopathy. Enfortumab vedotin was discontinued because of treatment-related peripheral neuropathy and dermatologic toxicity, and pembrolizumab monotherapy was continued. At the sixth cycle of pembrolizumab, FDG PET/CT revealed complete metabolic response. The patient remains progression-free for more than eight months after documentation of complete metabolic response.
conclusionThis case demonstrates sustained complete metabolic response following short-course enfortumab vedotin combined with pembrolizumab in metastatic UTUC and highlights the potential for durable disease control despite early discontinuation of enfortumab vedotin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.